MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia

Blood

Volumn 97, Issue 11, 2001, Pages 3605-3611

  Van Den Heuvel Eibrink, Marry M ^a,b,c   Wiemer, Erik A C ^a,b,c   De Boevere, Marjan J ^a,b,c   Van Der Holt, Bronno ^a,b,c   Vossebeld, Paula J M ^a,b,c   Pieters, Rob ^a,b,c   Sonneveld, Pieter ^a,b,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c Dutch Childhood Leukemia Study Group   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISOLONE; TIOGUANINE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; GENE EXPRESSION; GENE FUNCTION; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0035383769     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.11.3605     Document Type: Article

References (48)

1. Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood. 1992;79: 473-476.
2. Del Poeta G, Stasi R, Venditti A, et al. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia. 1994;8:388-394.
3. Del Poeta G, Stasi R, Aronica G, et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood. 1996;87: 1997-2004.
4. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multi-drug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study. Blood. 1997; 89:3323-3329.
5. Van den Heuvel-Elbrink MM, van der Holt B, te Boekhorst PA, et al. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br J Haematol. 1997;99:76-83.
6. Van den Heuvel-Eibrink MM, Sonneveld P, Pieters R. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther. 2000;38:94-110.
7. Willman CL. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol. 1997; 34(4 suppl 5):25-33.
8. Senent L, Jarque I, Martin G, et al. P-glycoprotein expression and prognostic value in acute myeloid leukemia. Haematologica. 1998;83:783-787.
9. Legrand O, Simonin G, Zittoun R, Marie JP. Both P-gp and MRP contribute to drug resistance in AML. Blood. 1999;94:1046-1056.
10. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP. P-gp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood. 1998;91:4480-4488,
11. Michieli M, Damiani D, Ermacora A, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br J Haematol. 1999; 104:328-335.
12. Mickley LA, Lee JS, Weng Z, et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood. 1998;91:1749-1756.
13. Mickley LA, Spengler BA, Knutsen TA, Biedler JL, Fojo T. Gene rearrangement: a novel mechanism for MDR-1 gene activation. J Clin Invest. 1997; 99:1947-1957.
14. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-625.
15. Mitelman F, ed. ISCN 1991: Guidelines for Cancer Cytogenetics: Supplement to an International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1991.
16. Lowenberg B, van Putten WL, Touw IP, Delwel R, Santini V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N Engl J Med. 1993;328:614-619.
17. Sugawara I, Kataoka I, Morishita Y, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 1988;48:1926-1929.
18. Mechetner EB, Roninson IB. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A. 1992;89:5824-5828.
19. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 1991;66:85-94.
20. Ludescher C, Thaler J, Drach D, et al. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br J Haematol. 1992;82:161-168.
21. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res. 1986;46:5125-5130.
22. Hunault M, Zhou D, Delmer A, et al. Multidrug resistance gene expression in acute myeloid leukemia: major prognostic significance for in vivo drug resistance to induction treatment. Ann Hematol. 1997;74:65-71.
23. Musto P, Cascavilla N, Di Renzo N, et al. Clinical relevance of immunocytochemical detection of multidrug resistance associated P-glycoprotein in hematologic malignancies. Tumori. 1990;76:353-359.
24. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood. 1991;78:586-592.
25. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996;56:3010-3020.
26. Guerci, A, Merlin JL, Missoum N, et al. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood. 1995;85:2147-nn 2153.
27. Maslak P, Hegewisch-Becker S, Godfrey L, Andreeff M. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia. Cytometry. 1994;17:84-93.
28. Michieli M, Giacca M, Fanin R, Damiani D, Geromin A, Baccarani M. Mdr-1 gene amplification in acute lymphoblasfic leukaemia prior to antileukaemic treatment. Br J Haematol. 1991;78: 288-289.
29. List AF. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia. 1996;10:937-942.
30. Ito Y, Tanimoto M, Kumazawa T, et al. Increased P-glycoprotein expression and multidrug-resistant gene (mdr1) amplification are infrequently found in fresh acute leukemia cells: sequential analysis of 15 cases at initial presentation and relapsed stage. Cancer. 1989;63:1534-1538.
31. Ino T, Miyazaki H, Isogai M, et al. Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome. Leukemia. 1994;8:1492-1497.
32. Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG, Mehta AB. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukemia. 1994;8:2163-2168.
33. Wood P, Burgess R, MacGregor A, Yin JA. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol. 1994;87: 509-514.
34. Kaczorowski S, Ochoka M, Aleksandrowicz R, Kaczorowska M, Matysiak M, Karwacki M. Expression of P-glycoprotein in children and adults with leukemia: correlation with clinical outcome. In: Hiddeman et al, eds. Acute Leukemias V: Experimental Approaches and Management of Refractory Diseases. Berlin, Heidelberg: Springer-Verlag; 1996:101-107.
35. Gekeler V, Frese G, Noller A, et al. Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias. Br J Cancer. 1992;66:507-517.
36. Beck J, Handgretinger R, Klingebiel T, et al. Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. Leukemia. 1996;10:426-433.
37. Sato H, Preisler H, Day R, et al. MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol. 1990;75:340-345.
38. Marie JP, Faussat-Subervitte AM, Zhou D, Zittoun R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia. 1993;7:825-831.
39. Sievers EL, Smith FO, Woods WG, et al. Cell surface expression of the multidrug resistance P-glycopretein (P- 170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group. Leukemia. 1995;9:2042-2048.
40. Gekeler V, Frese G, Diddens H, Probst H. Expression of a P-glycoprotein gene is inducible in a multidrug resistant human leukemia cell line. Biochem Biophys Res Commun. 1988; 155:754-760.
41. Ma DD, Scurr RD, Davey RA, et al. Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. Lancet. 1987;1:135-137.
42. Baas F, Jongsma AP, Brexterman HJ, et al Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. Cancer Res. 1990;50:5392-5398.
43. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989;81:116-124.
44. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst.1993;85:632-639.
45. Gekeler V, Beck J, Noller A, et al. Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias. Ann Hematol. 1994;69(suppl 1):S19-S24.
46. Brock I, Hipfner DR, Nielsen BS, et al. Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res. 1995;55:459-462.
47. Matsumoto Y, Takano H, Fojo T. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype. Cancer Res. 1997;57: 5086-5092.
48. Knutsen T, Mickley LA, Ried T, et al. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P- glycoprotein, in drug-selected cell lines and patients with drug refractory ALL. Genes Chromosomes Cancer. 1998;23:44-54.